https://stockhead.cmail19.com/t/d-l-...-yupddjlly-yk/
Printable View
From FNArena ,could hurt FPH too.
"Brokers were universally disappointed by ResMed’s ((RMD)) margin outcome in the fourth quarter, though revenues were around the forecast level and margins are expected to improve. Only days after the release, market sentiment received an additional hit as US pharmaceutical Eli Lilly announced a fast-tracked trial for its successful obesity drug, tirzepatide, specifically targeting the CPAP mkt"